Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SRPT vs ACAD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SRPT Captures Overall Composite Edge (37.8 SELL vs 42.0 HOLD), While ACAD Leads 4–2 on Growth & Valuation Pillars
SRPT Overall Winner
6-Pillar Tally: SRPT 2 – 4 ACAD
Matrix Metrics: SRPT 2 – 8 ACAD
As of Nov 16, 2026, Sarepta Therapeutics,, Inc. (SRPT) captures the overall head-to-head institutional edge over Acadia Pharmaceuticals Inc. (ACAD) on higher Unified Composite conviction (37.8/100 SELL vs. 42.0/100 HOLD) after splitting the core matrix 2–8 (led by Valuation Multiples, Options & Positioning), while ACAD wins 4–2 across the 6-pillar growth and valuation breakdown. SRPT trades at $15.14 (10.8x Forward P/E, -0.4% operating margin) versus ACAD at $19.07 (17.8x Forward P/E, 10.2% operating margin).
- Composite vs. Pillar Nuance: While ACAD currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. SRPT 37.8/100 SELL), SRPT captures the overall institutional head-to-head verdict (2–8 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-0.4% vs. 10.2% operating margin) and revenue trajectory (-4.5% vs. +22.8% YoY).
- Technical & Structure Timing Caution: SRPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.0); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SRPT vs ACAD
SRPT
Head-to-Head Winner
Sarepta Therapeutics,, Inc. Common Stock
$15.14
-5.76% 1D
Market Cap
$1.7B
TTM Revenue
$1.96B
Forward P/E
10.8x
Beta / 30D Vol
1.47β · 58% Vol
Unified Composite Score
37.8
SELL
Tech 32.0
Fund 51.0
Flow 71.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
ACAD
Acadia Pharmaceuticals Inc.
$19.07
+1.71% 1D
Market Cap
$3.1B
TTM Revenue
$1.20B
Forward P/E
17.8x
Beta / 30D Vol
0.11β · 93% Vol
Unified Composite Score
42.0
HOLD
Tech 43.0
Fund 52.0
Flow 68.0
Mom 50.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (SRPT 2 – 4 ACAD)
1. Valuation Multiples
SRPT
Forward P/E
10.8x
17.8x
Trailing P/E
N/M
8.6x
PEG Ratio
N/M
N/M
EV / Revenue
1.2x
2.4x
2. Growth & Scale
ACAD
Revenue Growth (YoY)
-4.5%
+22.8%
Earnings Growth (YoY)
N/A
-26.2%
TTM Revenue (USD)
$1.96B
$1.20B
Market Cap
$1.7B
$3.1B
3. Profitability & Quality
ACAD
Gross Margin
23.4%
63.9%
Operating Margin
-0.4%
10.2%
Net Profit Margin
-5.9%
30.1%
Return on Equity (ROE)
-8.1%
31.4%
4. Balance Sheet & Cash Flow
ACAD
Cash Generation (TTM)
$172M
$181M
Cash Flow Margin
8.8%
15.0%
Net Cash / Leverage
$580M Net Debt (0.69x D/E)
$251M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SRPT
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
54.5% (7th %ile)
42.6% (4th %ile)
Put/Call OI Skew
0.66x (Call-Skewed)
0.33x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
ACAD
OpEx & R&D Intensity
23.8% of Rev ($466M)
53.7% of Rev ($646M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SRPT (2) vs ACAD (8)| Institutional Metric | SRPT | ACAD | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.7B | $3.1B | ACAD | |
| Trailing P/E Ratio | N/M | 8.6x | ACAD | |
| Forward P/E Ratio | 10.8x | 17.8x | SRPT | |
| Revenue Growth (YoY) | -4.5% | +22.8% | ACAD | |
| Operating Margin (TTM) | -0.4% | 10.2% | ACAD | |
| Net Profit Margin | -5.9% | 30.1% | ACAD | |
| Return on Equity (ROE) | -8.1% | 31.4% | ACAD | |
| 52-Week Range Position | 5% ($15–$25) | 21% ($16–$31) | ACAD | |
| Beta / 30D Volatility | 1.47β · 58% Vol | 0.11β · 93% Vol | SRPT | |
| Unified Institutional Score | 37.8 / 100 (SELL) | 42.0 / 100 (HOLD) | ACAD | |
| Trailing 12M Revenue (USD) | $1.96B | $1.20B | Scale | |
| Gross Profit Margin (TTM) | 23.4% | 63.9% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.2x EV/Rev | N/M PEG · 2.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $172M ($580M Net Debt (0.69x D/E)) | $181M ($251M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ACAD +11.18 pp
3M Horizon
SRPT +20.85 pp
6M Horizon
ACAD +3.14 pp
1Y Horizon
SRPT +4.31 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRPT Revenue | ACAD Revenue | SRPT Op. Margin | ACAD Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $300M | $220M | -114.1% | -110.6% | ACAD |
| FY2019 | $380M | $340M | -185.3% | -72.7% | ACAD |
| FY2020 | $460M | $440M | -123.8% | -64.9% | ACAD |
| FY2021 | $610M | $480M | -75.1% | -35.2% | ACAD |
| FY2022 | $840M | $520M | -63.5% | -43.2% | ACAD |
| FY2023 | $1.14B | $730M | -23.4% | -10.1% | ACAD |
| FY2024 | $1.79B | $960M | 12.2% | 24.1% | ACAD |
| FY2025 | $1.86B | $1.07B | -37.5% | 9.8% | ACAD |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SRPT
BREAKDOWN
Current IV
54.5%
IV Percentile
7th %ile
Put/Call OI Skew
0.66x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact SRPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ACAD
BREAKDOWN
Current IV
42.6%
IV Percentile
4th %ile
Put/Call OI Skew
0.33x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SRPT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
23.8% of Rev ($466M)
90D Engineering Disclosures
0 Published
ACAD Moat Profile
Scale & Operating Efficiency Moat
Biotechnology Operator
OpEx & R&D Reinvestment
53.7% of Rev ($646M)
90D Engineering Disclosures
0 Published
Investor FAQ SRPT vs ACAD Key Questions & Quantitative Answers
As of Nov 16, 2026, Sarepta Therapeutics,, Inc. (SRPT) captures the overall head-to-head institutional edge over Acadia Pharmaceuticals Inc. (ACAD) on higher Unified Composite conviction (37.8/100 SELL vs. 42.0/100 HOLD) after splitting the core matrix 2–8 (led by Valuation Multiples, Options & Positioning), while ACAD wins 4–2 across the 6-pillar growth and valuation breakdown. SRPT trades at $15.14 (10.8x Forward P/E, -0.4% operating margin) versus ACAD at $19.07 (17.8x Forward P/E, 10.2% operating margin). Composite vs. Pillar Nuance: While ACAD currently prints a higher short-term Unified Composite Score (42.0/100 HOLD vs. SRPT 37.8/100 SELL), SRPT captures the overall institutional head-to-head verdict (2–8 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-0.4% vs. 10.2% operating margin) and revenue trajectory (-4.5% vs. +22.8% YoY). Technical & Structure Timing Caution: SRPT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.0); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ACAD leads the Growth & Scale pillar: SRPT posts -4.5% YoY revenue growth and N/A YoY earnings growth on $1.96B TTM revenue (23.4% gross margin, -0.4% operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SRPT cumulative revenue shifted +520.0% while ACAD shifted +386.4%. In operating R&D and SG&A reinvestment, SRPT deploys 23.8% of Rev ($466M) (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.
SRPT screens cheaper on headline valuation multiples. SRPT trades at 10.8x Forward P/E, N/M Trailing P/E, N/M PEG, and 1.2x EV/Revenue (8.8% FCF margin), whereas ACAD trades at 17.8x Forward P/E, 8.6x Trailing P/E, N/M PEG, and 2.4x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRPT (-8.1% ROE) versus ACAD (31.4% ROE) capital efficiency.
In options market volatility and institutional positioning, SRPT carries 54.5% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 58% Vol realized risk). By comparison, ACAD carries 42.6% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.33x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.11β · 93% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ACAD vs SRPT · Reverse Pair
SRPT vs ALNY
· Sector Peer
SRPT vs BMRN
· Sector Peer
SRPT vs IONS
· Sector Peer
ACAD vs ALNY
· Sector Peer
ACAD vs BMRN
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem